Related Experiment Video

Updated: Jan 1, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Min Yuan1,2, Li-Li Huang1,2, Jian-Hua Chen1,3

  • 11Department of Oncology, Dermatology Hospital, Tongji University School of Medicine, Shanghai, 200443 China.

Signal Transduction and Targeted Therapy
|December 25, 2019
PubMed

Insights

Targeted therapy is revolutionizing non-small-cell lung cancer (NSCLC) treatment, moving beyond traditional chemotherapy. Future advancements in lung cancer care will integrate targeted therapy, immunotherapy, and chemotherapy based on molecular tumor profiles.

Area of Science:

  • Oncology
  • Medical research

Background:

  • Lung cancer is a leading cause of cancer mortality globally, with millions of new cases and deaths annually.
  • Non-small-cell lung cancer (NSCLC) management is evolving, with targeted therapy offering new treatment avenues.
  • Traditional chemotherapy is not universally optimal for all NSCLC patients.

Purpose of the Study:

  • To review and analyze recent literature on targeted therapy in lung cancer.
  • To discuss key molecular pathways targeted in NSCLC treatment.
  • To examine ongoing clinical trials investigating novel lung cancer therapies.

Main Methods:

  • Literature review and analysis of recent scientific publications.
  • Examination of molecular pathways implicated in NSCLC pathogenesis and treatment response.
  • Survey of current clinical trials in lung cancer therapeutics.

Main Results:

  • Targeted therapy has become a crucial component in managing NSCLC.
  • Understanding tumor molecular features is essential for personalized therapeutic decisions.
  • Ongoing clinical trials explore various targeted agents and combination strategies.

Conclusions:

  • Therapeutic decisions for lung cancer should be personalized based on molecular tumor characteristics.
  • The combination of targeted therapy, immunotherapy, and chemotherapy holds promise for future lung cancer treatment advancements.
  • Continued research and clinical trials are vital for optimizing lung cancer management.
Keywords:
Lung cancerTarget identification

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

288
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K